Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
Jama CardiologyPeer ReviewedArman Qamar +92018Journals
Little is known about the heterogeneity in low-density lipoprotein cholesterol levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor medications.
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support